NYSEARCA:HEB - NYSE Arca -
1.8
-0.01 (-0.55%)
The current stock price of HEB is 1.8 null. In the past month the price decreased by -19.28%. In the past year, price decreased by -85.12%.
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
HEMISPHERX BIOPHARMA INC
2117 SW HIGHWAY 484
OCALA FL 34473
CEO: Thomas K. Equels
Phone: 215-988-0080
The current stock price of HEB is 1.8 null. The price decreased by -0.55% in the last trading session.
The exchange symbol of HEMISPHERX BIOPHARMA INC is HEB and it is listed on the NYSE Arca exchange.
HEB stock is listed on the NYSE Arca exchange.
HEMISPHERX BIOPHARMA INC (HEB) has a market capitalization of 4.40M null. This makes HEB a Nano Cap stock.
HEMISPHERX BIOPHARMA INC (HEB) has a resistance level at 1.93. Check the full technical report for a detailed analysis of HEB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HEB does not pay a dividend.
HEMISPHERX BIOPHARMA INC (HEB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.54).
ChartMill assigns a fundamental rating of 2 / 10 to HEB. HEB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months HEB reported a non-GAAP Earnings per Share(EPS) of -5.540000000000001. The EPS decreased by -2418.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -3284.04% | ||
ROA | -73.02% | ||
ROE | -153.97% | ||
Debt/Equity | 0.37 |
ChartMill assigns a Buy % Consensus number of 60% to HEB. The Buy consensus is the average rating of analysts ratings from 1 analysts.